ATE305302T1 - Heterozyklische verbindungen mit sulfonamid- gruppen - Google Patents
Heterozyklische verbindungen mit sulfonamid- gruppenInfo
- Publication number
- ATE305302T1 ATE305302T1 AT00985953T AT00985953T ATE305302T1 AT E305302 T1 ATE305302 T1 AT E305302T1 AT 00985953 T AT00985953 T AT 00985953T AT 00985953 T AT00985953 T AT 00985953T AT E305302 T1 ATE305302 T1 AT E305302T1
- Authority
- AT
- Austria
- Prior art keywords
- ring
- atom
- nitrogen atom
- heterocyclic compounds
- hydrogen
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical group NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- -1 -CH2- Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229940100389 Sulfonylurea Drugs 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP37548999 | 1999-12-28 | ||
| PCT/JP2000/009326 WO2001047891A1 (en) | 1999-12-28 | 2000-12-27 | Heterocyclic compounds having sulfonamide groups |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE305302T1 true ATE305302T1 (de) | 2005-10-15 |
Family
ID=18505601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00985953T ATE305302T1 (de) | 1999-12-28 | 2000-12-27 | Heterozyklische verbindungen mit sulfonamid- gruppen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6787534B2 (de) |
| EP (1) | EP1243583B1 (de) |
| JP (1) | JP4234344B2 (de) |
| KR (1) | KR100641802B1 (de) |
| CN (1) | CN1217936C (de) |
| AT (1) | ATE305302T1 (de) |
| AU (1) | AU776933B2 (de) |
| CA (1) | CA2395772C (de) |
| DE (1) | DE60022906T2 (de) |
| ES (1) | ES2246922T3 (de) |
| HU (1) | HUP0203973A3 (de) |
| MX (1) | MXPA02006474A (de) |
| NO (1) | NO324268B1 (de) |
| NZ (1) | NZ519380A (de) |
| RU (1) | RU2239631C2 (de) |
| WO (1) | WO2001047891A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4542783B2 (ja) * | 2002-03-05 | 2010-09-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤 |
| WO2003080586A1 (en) * | 2002-03-21 | 2003-10-02 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| US7030115B2 (en) | 2002-03-21 | 2006-04-18 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| EP1731507A1 (de) | 2005-04-26 | 2006-12-13 | Institut National des Sciences Appliquees de Rouen (INSA) | Neue heterocyclische Verbindungen, ihre Herstellung und ihre Anwendung als Arzneimittel besonders als Anti-alzheimer mittel |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| WO2007008942A2 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
| US7470787B2 (en) * | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| US7989622B2 (en) * | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| KR20080093123A (ko) * | 2006-02-13 | 2008-10-20 | 에프. 호프만-라 로슈 아게 | 당뇨병 치료용 헤테로바이사이클릭 설폰아마이드 유도체 |
| MX2009001036A (es) * | 2006-08-04 | 2009-04-23 | Merz Pharma Gmbh & Co Kgaa | Pirazolopirimidinas, proceso para su preparacion y su uso como medicina. |
| ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
| RU2418003C2 (ru) * | 2006-11-10 | 2011-05-10 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Антиангиогенные соединения |
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| TWI425945B (zh) * | 2007-05-28 | 2014-02-11 | Seldar Pharma Inc | 四氫異喹啉－１－酮衍生物或其鹽 |
| US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3828172A1 (de) | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Hemmer mit doppelmechanismus zur behandlung von erkrankungen |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2010138588A2 (en) * | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| JPWO2011043359A1 (ja) | 2009-10-06 | 2013-03-04 | 協和発酵キリン株式会社 | 芳香族複素環化合物を含有する医薬 |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| ES2603129T3 (es) | 2010-11-23 | 2017-02-23 | Abbvie Ireland Unlimited Company | Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2 |
| US8951993B2 (en) * | 2011-02-24 | 2015-02-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phosphorus containing compounds as protein kinase inhibitors |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2852377T3 (es) | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
| CN104447536B (zh) * | 2014-10-25 | 2017-04-12 | 大连理工大学 | 一种n‑2‑喹啉基芳基磺酰胺类化合物的制备方法 |
| WO2016087593A1 (en) * | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| KR102579582B1 (ko) | 2015-11-17 | 2023-09-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 키나아제 억제제 및 이의 중간체의 제조 방법 |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| AU2018243687C1 (en) | 2017-03-31 | 2020-12-24 | Alcon Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2019115768A1 (en) | 2017-12-15 | 2019-06-20 | Bayer Animal Health Gmbh | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives |
| CA3112391A1 (en) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2020172615A1 (en) * | 2019-02-22 | 2020-08-27 | Glaukos Corporation | Compounds for the treatment of ocular disease |
| GB201919214D0 (en) * | 2019-12-23 | 2020-02-05 | Ucb Biopharma Sprl | Tetrahydrobenzo-quinoline sulfonamide derivatives useful as IGE modulators |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| AU2023235313A1 (en) | 2022-03-17 | 2024-10-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD9688A (de) * | ||||
| DE9688C (de) | T. REMUS in Plauen bei Dresden | Filter | ||
| GB662798A (en) | 1948-05-06 | 1951-12-12 | American Cyanamid Co | Improvements in or relating to the production of sulphonamides and intermediates thereof |
| NL80628C (de) | 1949-07-23 | |||
| US3157684A (en) * | 1961-02-13 | 1964-11-17 | Atomic Energy Authority Uk | Tritiated-2-methyl-naphthaquinol-(1, 4)-diphosphoric acids |
| US3801321A (en) | 1972-07-18 | 1974-04-02 | Eastman Kodak Co | Photothermographic element,composition and process |
| GB1492029A (en) * | 1974-01-30 | 1977-11-16 | Bellon R Lab | 4-oxo-1,4-dihydro-1,6-benzo-(h)-naphthyridine-3-carboxylic acid derivatives useful as anti-bacterial agents and their preparation |
| US4343804A (en) * | 1979-03-26 | 1982-08-10 | A. H. Robins Company, Inc. | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds |
| US4333760A (en) * | 1980-08-22 | 1982-06-08 | E. I. Du Pont De Nemours And Company | Herbicidal sulfonamides |
| JPS59220733A (ja) * | 1983-05-30 | 1984-12-12 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料 |
| DE3422824A1 (de) * | 1984-06-20 | 1986-01-02 | Celamerck Gmbh & Co Kg, 6507 Ingelheim | Neue herbizid wirksame sulfonylharnstoffe |
| EP0215200B1 (de) | 1985-06-24 | 1992-09-09 | Merck & Co. Inc. | Verwendung von sulfanilamido Quinoxalinen zur Behandlung von neoplastischen Krankheiten |
| AU600992B2 (en) * | 1986-10-28 | 1990-08-30 | Smith Kline & French Laboratories Limited | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| DE3804990A1 (de) | 1988-02-18 | 1989-08-31 | Basf Ag | Herbizid wirksame, heterocyclisch substituierte sulfonamide |
| JPH02149562A (ja) * | 1988-11-30 | 1990-06-08 | Nisshin Flour Milling Co Ltd | 相間移動触媒を用いた１，４−ジヒドロピリジン誘導体の製造方法 |
| NZ233641A (en) * | 1989-05-16 | 1992-07-28 | Merrell Dow Pharma | Quinoline and thienopyridine derivatives and excitatory amino acid antagonistic pharmaceutical compositions |
| JPH03150560A (ja) * | 1989-11-08 | 1991-06-26 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| DE4102234A1 (de) * | 1991-01-23 | 1992-07-30 | Dresden Arzneimittel | Neue (alpha)-aminochinolinoyl-(3)-penicilline, verfahren zu deren herstellung und diese enthaltende antibakterielle mittel |
| JPH06199047A (ja) * | 1993-01-08 | 1994-07-19 | New Oji Paper Co Ltd | 感熱記録体 |
| WO1995007276A1 (en) * | 1993-09-10 | 1995-03-16 | Eisai Co., Ltd. | Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives |
| JPH07138493A (ja) * | 1993-11-19 | 1995-05-30 | Konica Corp | 金属錯体化合物及び該化合物を用いた光記録媒体 |
| US5529999A (en) | 1994-03-04 | 1996-06-25 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| FR2725719B1 (fr) | 1994-10-14 | 1996-12-06 | Jouveinal Inst Rech | Diazepino-indoles inhibiteurs de phosphodiesterases iv |
| KR19990067010A (ko) | 1995-10-23 | 1999-08-16 | 오스테오스크린, 인코포레이티드 | 골결핍 상태의 치료용 조성물 및 그 치료방법 |
| DE19727117A1 (de) | 1997-06-26 | 1999-01-07 | Boehringer Ingelheim Pharma | Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| MXPA02007249A (es) * | 2000-02-03 | 2002-12-09 | Eisai Co Ltd | Inhibidor de la expresion de integrina. |
-
2000
- 2000-12-27 US US10/149,253 patent/US6787534B2/en not_active Expired - Fee Related
- 2000-12-27 HU HU0203973A patent/HUP0203973A3/hu unknown
- 2000-12-27 JP JP2001549363A patent/JP4234344B2/ja not_active Expired - Fee Related
- 2000-12-27 DE DE60022906T patent/DE60022906T2/de not_active Expired - Lifetime
- 2000-12-27 ES ES00985953T patent/ES2246922T3/es not_active Expired - Lifetime
- 2000-12-27 WO PCT/JP2000/009326 patent/WO2001047891A1/ja not_active Ceased
- 2000-12-27 EP EP00985953A patent/EP1243583B1/de not_active Expired - Lifetime
- 2000-12-27 AU AU22283/01A patent/AU776933B2/en not_active Ceased
- 2000-12-27 RU RU2002120515/04A patent/RU2239631C2/ru not_active IP Right Cessation
- 2000-12-27 CN CN008180059A patent/CN1217936C/zh not_active Expired - Fee Related
- 2000-12-27 KR KR1020027008281A patent/KR100641802B1/ko not_active Expired - Fee Related
- 2000-12-27 NZ NZ519380A patent/NZ519380A/en not_active IP Right Cessation
- 2000-12-27 AT AT00985953T patent/ATE305302T1/de not_active IP Right Cessation
- 2000-12-27 MX MXPA02006474A patent/MXPA02006474A/es active IP Right Grant
- 2000-12-27 CA CA2395772A patent/CA2395772C/en not_active Expired - Fee Related
-
2002
- 2002-06-26 NO NO20023097A patent/NO324268B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60022906T2 (de) | 2006-07-06 |
| CA2395772A1 (en) | 2001-07-05 |
| DE60022906D1 (de) | 2006-02-09 |
| HUP0203973A2 (hu) | 2003-03-28 |
| CA2395772C (en) | 2010-09-28 |
| JP4234344B2 (ja) | 2009-03-04 |
| NZ519380A (en) | 2004-10-29 |
| US6787534B2 (en) | 2004-09-07 |
| KR100641802B1 (ko) | 2006-11-02 |
| RU2002120515A (ru) | 2004-01-10 |
| KR20020068388A (ko) | 2002-08-27 |
| CN1414952A (zh) | 2003-04-30 |
| NO20023097D0 (no) | 2002-06-26 |
| AU776933B2 (en) | 2004-09-23 |
| RU2239631C2 (ru) | 2004-11-10 |
| EP1243583B1 (de) | 2005-09-28 |
| NO20023097L (no) | 2002-08-28 |
| HUP0203973A3 (en) | 2004-07-28 |
| NO324268B1 (no) | 2007-09-17 |
| ES2246922T3 (es) | 2006-03-01 |
| MXPA02006474A (es) | 2002-11-29 |
| US20030144507A1 (en) | 2003-07-31 |
| WO2001047891A1 (en) | 2001-07-05 |
| EP1243583A1 (de) | 2002-09-25 |
| EP1243583A4 (de) | 2003-08-20 |
| AU2228301A (en) | 2001-07-09 |
| CN1217936C (zh) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE305302T1 (de) | Heterozyklische verbindungen mit sulfonamid- gruppen | |
| DE69903923D1 (de) | Bizyklische pyrrolderivate als mcp-1 inhibitoren | |
| NO20015448L (no) | Kinolinderivater som inhibitorer av MEK-enzymer | |
| AP1902A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| NO20060219L (no) | Forbindelser | |
| DE60221098D1 (de) | Kondensierte heterocyclische derivate | |
| DK1052254T3 (da) | Nitrogen-holdig heterocykliske derivater og medicin deraf | |
| DE60140456D1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| DE60315265D1 (de) | Stickstoffhaltige heterocyclische verbindung und arzneimittel davon | |
| NO20023456L (no) | Nitrogenholdige forbindelser og farmasöytiske preparater inneholdende de samme | |
| DE60322224D1 (de) | Kondensierte heterozyklische verbindungen als petidase inhibitoren | |
| NO20076006L (no) | Acetylenderivater | |
| DE60014043D1 (de) | Flouride von 4-substituierten piperidin-derivaten | |
| DE60217185D1 (de) | MIKROBIOZIDE N-PHENYL-N-i4-(4-PYRIDYL)-2-PYRIMIDIN-2-YLö-AMIN-DERIVATE | |
| ATE293600T1 (de) | Antibakterielle mittel | |
| HUP0001245A1 (hu) | Új eritromicinszármazékok, eljárás a vegyületek előállítására és gyógyszerként történő alkalmazásuk | |
| EA200001248A1 (ru) | Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции | |
| ATE449773T1 (de) | Homomorpholinoxazolidinone als antibakterielle mittel | |
| NO20053302L (no) | Imidazolderivater med affinitet for alfa 2-reseptoraktivitet. | |
| DE60135002D1 (de) | Arzneizusammensetzungen enthaltend oxapenem-3-carbonsäuren | |
| GB0427491D0 (en) | Process and compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |